Unnamed: 0,title,date,stock,sentiment
559389.0,GylcoMimetics To Present On 'Transcriptome profiling of ST3GAL4 and FUT7' At AACR June 22-24,2020-05-15 12:33:00-04:00,GLYC,neutral
559390.0,GlycoMimetics to Present New Preclinical Data Highlighting Biomarkers and Potential Expanded Pipeline Opportunities at Virtual AACR Annual Meeting 2020,2020-05-15 12:30:00-04:00,GLYC,positive
559391.0,"The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO",2020-05-01 07:54:00-04:00,GLYC,neutral
559392.0,"GlycoMimetics Q1 EPS $(0.180) Beats $(0.300) Estimate, Sales $9.000K",2020-05-01 07:05:00-04:00,GLYC,neutral
559393.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,GLYC,negative
559394.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,GLYC,neutral
559395.0,"H.C. Wainwright Reiterates Buy on GlycoMimetics, Lowers Price Target to $16",2020-03-02 07:28:00-05:00,GLYC,negative
559396.0,GlycoMimetics Q4 EPS $(0.34) Down From $(0.32) YoY,2020-02-28 08:08:00-05:00,GLYC,neutral
559397.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,GLYC,neutral
559398.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,GLYC,positive
559399.0,GlycoMimetics Announces US Patent Issuance And FDA Orphan Drug Designation For GMI-1359 Program,2020-02-04 09:54:00-05:00,GLYC,neutral
559400.0,GlycoMimetics Reports First Patient With Advanced Breast Cancer Dosed In GMI-1359 Trial,2020-01-30 09:03:00-05:00,GLYC,negative
559401.0,23 Biotechnology Stocks Moving In Monday's After-Market Session,2020-01-27 23:45:00-05:00,GLYC,neutral
559402.0,36 Healthcare Stocks Moving In Monday's After-Market Session,2020-01-27 23:41:00-05:00,GLYC,neutral
559403.0,66 Biggest Movers From Yesterday,2019-11-22 04:50:00-05:00,GLYC,neutral
559404.0,45 Stocks Moving In Thursday's Mid-Day Session,2019-11-21 12:11:00-05:00,GLYC,neutral
559405.0,"Glycomimetics 8-K Shows Updated Guidance For Phase 3 Trial Of Uproleselan In Relapsed/Refractory AML, Now Sees Top-Line Results In 2021",2019-11-21 06:12:00-05:00,GLYC,positive
559406.0,"Benzinga's Top Upgrades, Downgrades For November 14, 2019",2019-11-14 09:56:00-05:00,GLYC,positive
559407.0,"Roth Capital Initiates Coverage On GlycoMimetics with Buy Rating, Announces $12 Price Target",2019-11-14 06:28:00-05:00,GLYC,neutral
559408.0,GlycoMimetics Earlier Reported Q3 EPS $(0.31) Beats $(0.39) Estimate,2019-11-07 09:49:00-05:00,GLYC,neutral
559409.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,GLYC,negative
559410.0,80 Biggest Movers From Yesterday,2019-09-11 05:11:00-04:00,GLYC,neutral
559411.0,50 Stocks Moving In Tuesday's Mid-Day Session,2019-09-10 12:19:00-04:00,GLYC,neutral
559412.0,46 Stocks Moving In Friday's Mid-Day Session,2019-09-06 12:09:00-04:00,GLYC,neutral
559413.0,60 Biggest Movers From Friday,2019-08-19 05:00:00-04:00,GLYC,neutral
559414.0,41 Stocks Moving In Friday's Mid-Day Session,2019-08-16 12:27:00-04:00,GLYC,neutral
559415.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,GLYC,positive
559416.0,70 Biggest Movers From Yesterday,2019-08-06 04:46:00-04:00,GLYC,neutral
559417.0,Mid-Afternoon Market Update: Dow Falls Over 800 Points; Cars.com Shares Slide,2019-08-05 14:26:00-04:00,GLYC,positive
559418.0,New 52-Week Lows For Monday Morning,2019-08-05 13:16:00-04:00,GLYC,negative
559419.0,45 Stocks Moving In Monday's Mid-Day Session,2019-08-05 12:37:00-04:00,GLYC,neutral
559420.0,"A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019",2019-08-05 12:21:00-04:00,GLYC,neutral
559421.0,Mid-Day Market Update: Crude Oil Down Over 1%; Allakos Shares Spike Higher,2019-08-05 12:08:00-04:00,GLYC,negative
559422.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Monday., August 5, 2019",2019-08-05 10:44:00-04:00,GLYC,positive
559423.0,Mid-Morning Market Update: Markets Open Lower; Tyson Foods Earnings Top Views,2019-08-05 10:43:00-04:00,GLYC,negative
559424.0,"Benzinga's Top Upgrades, Downgrades For August 5, 2019",2019-08-05 10:29:00-04:00,GLYC,positive
559425.0,What Caused The Opening Gap In GlycoMimetics?,2019-08-05 09:55:00-04:00,GLYC,neutral
559426.0,GlycoMimetics shares are trading lower after the company announced Pfizer's Phase 3 clinical trial evaluating Rivipansel in Sickle Cell did not meet its Primary or key Secondary endpoints.,2019-08-05 09:34:00-04:00,GLYC,neutral
559427.0,10 Biggest Price Target Changes For Monday,2019-08-05 08:47:00-04:00,GLYC,neutral
559428.0,GlycoMimetics Falls 50% After Disappointing Results For Sickle Cell Drug Trial,2019-08-05 08:42:00-04:00,GLYC,negative
559429.0,25 Stocks Moving In Monday's Pre-Market Session,2019-08-05 07:46:00-04:00,GLYC,neutral
559430.0,GlycoMimetics Earlier Announces Pfizer's Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease Did Not Meet its Primary or Key Secondary Endpoints,2019-08-05 07:41:00-04:00,GLYC,neutral
559431.0,Jefferies Downgrades GlycoMimetics to Hold,2019-08-05 07:11:00-04:00,GLYC,neutral
559432.0,"SunTrust Robinson Humphrey Downgrades GlycoMimetics to Hold, Lowers Price Target to $5",2019-08-05 07:09:00-04:00,GLYC,negative
559433.0,"Piper Jaffray Downgrades GlycoMimetics to Neutral, Lowers Price Target to $6",2019-08-05 07:07:00-04:00,GLYC,negative
559434.0,29 Healthcare Stocks Moving In Friday's After-Market Session,2019-08-02 20:51:00-04:00,GLYC,neutral
559435.0,GlycoMimetics Q2 EPS $(0.37) Misses $(0.36) Estimate,2019-08-01 08:09:00-04:00,GLYC,negative
559436.0,58 Biggest Movers From Yesterday,2019-07-23 05:39:00-04:00,GLYC,neutral
559437.0,GlycoMimetics Option Alert: Aug 16 $17.5 Calls at the Ask: 715 @ $1.25 vs 8809 OI; Earnings 8/8 After Close [est] Ref=$12.89,2019-07-16 10:13:00-04:00,GLYC,positive
559438.0,31 Stocks Moving In Tuesday's Pre-Market Session,2019-06-11 08:09:00-04:00,GLYC,neutral
559439.0,52 Biggest Movers From Yesterday,2019-06-11 04:43:00-04:00,GLYC,neutral
559440.0,GlycoMimetics S-3 Shows Registration For $250M Mixed Securities Offering,2019-05-17 16:43:00-04:00,GLYC,positive
559441.0,GlycoMimetics Reports Enrollment Completed For Phase 3 Trial Evaluating Rivipansel In Sickle Cell Disease,2019-05-06 09:08:00-04:00,GLYC,neutral
559442.0,"The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data",2019-05-02 08:16:00-04:00,GLYC,positive
559443.0,GlycoMimetics Q1 EPS $(0.33) Beats $(0.34) Estimate,2019-05-02 08:00:00-04:00,GLYC,neutral
559444.0,GlycoMimetics Reports Enrollment Of First Patient In NCI-Sponsored Phase 3 Trial Of Uproleselan In Acute Myeloid Leukemia,2019-04-23 09:15:00-04:00,GLYC,neutral
559445.0,GlycoMimetics Announces Publication of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial of GMI-1359,2019-04-22 09:01:00-04:00,GLYC,positive
559446.0,GlycoMimetics Reports Plans To Initiate Breast Cancer Trial To Evaluate GMI-1359,2019-04-12 09:01:00-04:00,GLYC,negative
559447.0,PiperJaffray Initiates Coverage On GlycoMimetics with Overweight Rating,2019-04-12 07:21:00-04:00,GLYC,negative
559448.0,GlycoMimetics Q4 EPS $(0.32) Misses $(0.30) Estimate,2019-03-06 07:43:00-05:00,GLYC,negative
559449.0,GlycoMimetics Announces Transition Plan for Board of Directors,2019-03-05 16:33:00-05:00,GLYC,neutral
559450.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,GLYC,positive
559451.0,"Benzinga's Top Upgrades, Downgrades For December 18, 2018",2018-12-18 09:27:00-05:00,GLYC,positive
559452.0,"H.C. Wainwright Initiates Coverage On GlycoMimetics with Buy Rating, Announces $24 Price Target",2018-12-18 08:34:00-05:00,GLYC,neutral
559453.0,"Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018",2018-12-14 11:03:00-05:00,GLYC,negative
559454.0,"The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch",2018-12-14 07:47:00-05:00,GLYC,neutral
559455.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018",2018-12-10 11:01:00-05:00,GLYC,negative
559456.0,"The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut",2018-12-07 08:04:00-05:00,GLYC,neutral
559457.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs",2018-12-02 17:51:00-05:00,GLYC,neutral
559458.0,GlycoMimetics Reports Enrollment Of First Patient In Global Phase 3 Trial Of Uproleselan In Relapsed/Refractory Acute Myeloid Leukemia,2018-11-19 09:01:00-05:00,GLYC,neutral
559459.0,"The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results",2018-11-15 08:10:00-05:00,GLYC,positive
559460.0,GlycoMimetics Q3 EPS $(0.27) Down From $(0.24) YoY,2018-11-02 07:31:00-04:00,GLYC,neutral
559461.0,"Glycomimetics 13G Filing From OppenheimerFunds Shows Raised Stake From ~2.96M Shares At End Of Last Qtr. To ~4.4M Shares, Or 10.28% Stake",2018-09-06 12:03:00-04:00,GLYC,positive
559462.0,GlycoMimetics Receives Japanese Patent For Uproleselan (GMI-1271),2018-08-14 09:01:00-04:00,GLYC,neutral
559463.0,GlycoMimetics Q2 EPS $(0.26) Beats $(0.34) Estimate,2018-08-09 16:35:00-04:00,GLYC,neutral
559464.0,50 Biggest Movers From Yesterday,2018-07-26 04:16:00-04:00,GLYC,neutral
559465.0,36 Stocks Moving In Wednesday's Mid-Day Session,2018-07-25 12:50:00-04:00,GLYC,neutral
559466.0,"GlycoMimetics 8-K Shows Pfizer Said Ongoing Phase 3 Trial With Rivipansel Is ~75% Enrolled, Pfizer Delayed Timeline For Complete Enrollment From 2H'18 To Early 2019, Top-Line Data Available From End OF 2018 To Q2'19",2018-07-25 08:41:00-04:00,GLYC,negative
559467.0,"Jefferies 2018 Global Healthcare Conference Continues Today, Presenters Include: bluebird bio, GlycoMimetics, Five Prime Therapeutics, GTx, ImmunoGen, Puma Biotech, and Deciphera Pharma",2018-06-07 07:13:00-04:00,GLYC,neutral
559468.0,"UPDATE: GlycoMimetics Will Collaborate With NCI, Alliance For Clinical Trials In Oncology To Conduct Randomized, Controlled Clinical Trial Tsting The Addition Of GMI-1271 to Standard 7&3 Regimen In Older Adults",2018-05-30 09:21:00-04:00,GLYC,neutral
559469.0,"GlycoMimetics Reports NCI-Sponsored Pivotal Trial Of GMI-1271 In Older, Newly Diagnosed AML Patients Fit For Intensive Chemotherapy",2018-05-30 09:19:00-04:00,GLYC,positive
559470.0,GlycoMimetics Q1 EPS $(0.33) Misses $(0.28) Estimate,2018-05-03 07:27:00-04:00,GLYC,negative
559471.0,GlycoMimetics Prices 7M Share Public Offering of Common Stock @$17/Share,2018-03-21 04:09:00-04:00,GLYC,positive
559472.0,15 Stocks Moving In Tuesday's Pre-Market Session,2018-03-20 08:20:00-04:00,GLYC,neutral
559473.0,7 Stocks Moving In Monday's After-Hours Session,2018-03-19 18:03:00-04:00,GLYC,neutral
559474.0,GlycoMimetics  Announces 4.5M Share Offering,2018-03-19 16:01:00-04:00,GLYC,positive
559475.0,44 Biggest Movers From Yesterday,2018-03-07 05:03:00-05:00,GLYC,neutral
559476.0,Mid-Afternoon Market Update: Freshpet Slides On Earnings Miss; CommerceHub Shares Surge,2018-03-06 14:30:00-05:00,GLYC,positive
559477.0,GycoMimetics Shares Down ~20% As Q4 EPS Miss Prompts Sell-Off,2018-03-06 12:54:00-05:00,GLYC,positive
559478.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-03-06 12:27:00-05:00,GLYC,neutral
559479.0,Mid-Day Market Update: Dow Falls Over 100 Points; Amedica Shares Spike Higher,2018-03-06 12:02:00-05:00,GLYC,positive
559480.0,Mid-Morning Market Update: Markets Mostly Higher; Ciena Profit Tops Expectations,2018-03-06 10:23:00-05:00,GLYC,positive
559481.0,25 Stocks Moving In Tuesday's Pre-Market Session,2018-03-06 08:09:00-05:00,GLYC,neutral
559482.0,"GlycoMimetics Reports Q4 EPS $(0.27) vs $(0.26) Est., No Sales",2018-03-06 07:36:00-05:00,GLYC,negative
559483.0,8 Stocks Moving In Monday's After-Hours Session,2018-03-05 18:32:00-05:00,GLYC,neutral
559484.0,GlycoMimetics Reports Design Of Phase 3 Trial Of GMI-1271 In Relapsed/Refractory AML,2018-03-05 16:04:00-05:00,GLYC,positive
559485.0,GlycoMimetics Enters into Agreement with HOVON to Initiate Study Startup Activities for Planned Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia,2018-02-08 09:04:00-05:00,GLYC,positive
559486.0,"GlycoMimetics Shares Strong On Heavy Volume, Setting New 52-Week High At $23.99, Now Up 9.2% At $23.80",2018-01-19 12:34:00-05:00,GLYC,positive
559487.0,40 Biggest Movers From Yesterday,2017-12-13 05:08:00-05:00,GLYC,neutral
559488.0,Mid-Afternoon Market Update: Crude Oil Down 1.5%; Proteostasis Therapeutics Shares Spike Higher,2017-12-12 14:32:00-05:00,GLYC,negative
559489.0,30 Stocks Moving In Tuesday's Mid-Day Session,2017-12-12 12:33:00-05:00,GLYC,neutral
559490.0,Mid-Day Market Update: Dow Rises Over 100 Points; Oasis Petroleum Shares Plummet,2017-12-12 12:01:00-05:00,GLYC,positive
559491.0,30 Stocks Moving In Tuesday's Pre-Market Session,2017-12-12 08:09:00-05:00,GLYC,neutral
559492.0,GlycoMimetic Gives an Update on Survival Rates for its Phase 1/2 Trial for GMI-1271,2017-12-12 07:05:00-05:00,GLYC,neutral
559493.0,GlycoMimetics Reports Q3 EPS $(0.24) vs $(0.28) Est.,2017-11-08 07:55:00-05:00,GLYC,neutral
559494.0,GlycoMimetics Says GMI-1271 Improves Efficacy and Safety of Chemotherapy in Phase 1/2 Study in 2 Acute Myeloid Leukemia (AML) Patient Populations,2017-11-01 09:19:00-04:00,GLYC,positive
559495.0,Seeing Notable Block Trade In GlycoMimetics; 1.6M Shares At $12.50,2017-10-11 14:30:00-04:00,GLYC,negative
559496.0,GlycoMimetics Secondary Offering Lockup Expires Today,2017-08-22 08:39:00-04:00,GLYC,neutral
559497.0,GlycoMimetics Reports Q2 EPS $(0.30) vs $(0.41) In Same Qtr. Last Year,2017-08-03 09:18:00-04:00,GLYC,neutral
559498.0,GlycoMimetics Reports Will Receive European Patent For GMI-1271,2017-07-06 09:00:00-04:00,GLYC,neutral
559499.0,Glycomimetics Pops to High of $12.19 on Volume,2017-06-16 15:54:00-04:00,GLYC,neutral
559500.0,18 Biggest Mid-Day Gainers For Tuesday,2017-06-06 12:30:00-04:00,GLYC,neutral
559501.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-06-06 08:12:00-04:00,GLYC,neutral
559502.0,Glycomimetics Spikes to High of $13.26 on Volume,2017-06-02 12:06:00-04:00,GLYC,neutral
559503.0,UPDATE: GlycoMimetics Says 'Patients with higher levels of novel biomarker were more likely to achieve response when GMI-1271 was added to standard therapy',2017-05-31 09:02:00-04:00,GLYC,positive
559504.0,UPDATE: GlycoMimetics Says 'Clinical trial now fully enrolled with 91 patients: 25 in newly diagnosed arm and 66 in relapsed refractory arm',2017-05-31 09:01:00-04:00,GLYC,neutral
559505.0,GlycoMimetics Reports Closing of Enrollment of Relapsed/Refractory AML Patient Cohort in Phase 2 Portion of GMI-1271 Trial,2017-05-31 09:01:00-04:00,GLYC,positive
559506.0,20 Stocks Moving In Wednesday's Pre-Market Session,2017-05-31 08:06:00-04:00,GLYC,neutral
559507.0,GlycoMimetics Reports GMI-1271 Received Orphan Drug Designation in the EU for Treatment for Acute Myeloid Leukemia,2017-05-25 09:26:00-04:00,GLYC,neutral
559508.0,15 Biggest Mid-Day Gainers For Wednesday,2017-05-24 12:30:00-04:00,GLYC,neutral
559509.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-05-24 08:11:00-04:00,GLYC,neutral
559510.0,GlycoMimetics Prices 7M Shares at $11.50/Share for Gross Proceeds ~$80.5M,2017-05-24 08:03:00-04:00,GLYC,negative
559511.0,"GlycoMimetics Terminated Sales Agreement with Cowen on May 23, 2017",2017-05-24 07:28:00-04:00,GLYC,positive
559512.0,GlycoMimetics Shares Up 9% Over Last Few Mins. of After-Hours Trade,2017-05-23 17:28:00-04:00,GLYC,positive
559513.0,GlycoMimetics Shares Indicated Up ~0.8% as Hearing Co.'s 6M Share Offering Expected to be Priced at $12/Share,2017-05-23 16:52:00-04:00,GLYC,positive
559514.0,GlycoMimetics Reports Offering of 6M Shares of Common Stock,2017-05-22 16:02:00-04:00,GLYC,positive
559515.0,12 Biggest Mid-Day Losers For Monday,2017-05-22 13:01:00-04:00,GLYC,negative
559516.0,22 Stocks Moving In Monday's Pre-Market Session,2017-05-22 08:07:00-04:00,GLYC,neutral
559517.0,15 Biggest Mid-Day Gainers For Friday,2017-05-19 12:42:00-04:00,GLYC,neutral
559518.0,22 Stocks Moving In Friday's Pre-Market Session,2017-05-19 08:11:00-04:00,GLYC,neutral
559519.0,"GlycoMimetics Shares Up 8% in Pre-Market Trade Fri., Follows ~99% Move Higher Thurs.; Hearing SunTrust Yesterday Evening Issued Positive Comments, Saying GMI-1271 Results Validates the E-Selectin Hypothesis; Reiterated $16 Price Target",2017-05-19 07:06:00-04:00,GLYC,positive
559520.0,Mid-Afternoon Market Update: Dow Rises Over 100 Points; Perry Ellis Shares Gain After Strong Q1 Results,2017-05-18 14:37:00-04:00,GLYC,positive
559521.0,15 Biggest Mid-Day Gainers For Thursday,2017-05-18 12:31:00-04:00,GLYC,neutral
559522.0,Mid-Day Market Update: Ascena Retail Tumbles On Weak Guidance; athenahealth Shares Surge,2017-05-18 12:12:00-04:00,GLYC,negative
559523.0,Mid-Morning Market Update: Markets Mostly Higher; Wal-Mart Profit Tops Estimates,2017-05-18 10:10:00-04:00,GLYC,positive
559524.0,Stifel's ASCO Abstract Cheat Sheet,2017-05-18 09:57:00-04:00,GLYC,negative
559525.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-05-18 08:09:00-04:00,GLYC,neutral
559526.0,"GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML",2017-05-18 06:39:00-04:00,GLYC,positive
559527.0,GlycoMimetics Reports GMI-1271 Received FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia,2017-05-17 16:13:00-04:00,GLYC,neutral
559528.0,Glycomimetics Reports Q1 EPS $(0.34) vs $(0.37) Est.,2017-05-08 09:02:00-04:00,GLYC,neutral
559529.0,"GlycoMimetics Reports Publication of Preclinical Data Showing Role of E-selectin Ligands in Multiple Myeloma: Showed Confers More Aggressive Disease, Greater Resistance to Standard of Care",2017-05-02 09:04:00-04:00,GLYC,positive
559530.0,GlycoMimetics to Present New Preclinical Data in Multiple Myeloma at AACR Annual Meeting 2017,2017-03-02 04:16:00-05:00,GLYC,neutral
559531.0,GlycoMimetics Reports Phase 1/2 Clinical Trial Results,2016-12-05 10:03:00-05:00,GLYC,neutral
559532.0,"American Society Of Hematology Meeting Begins Dec. 3rd, Day 1 of 4",2016-12-02 10:53:00-05:00,GLYC,neutral
559533.0,Jefferies London Health Care Conference Continues Today,2016-11-17 10:14:00-05:00,GLYC,positive
559534.0,GlycoMimetics Reports 'Data illustrate potential for synergy between drug candidate GMI-1359 and PD-L1 antagonists when used in combination to treat solid tumors',2016-11-08 09:05:00-05:00,GLYC,positive
559535.0,GlycoMimetics Reports 'Data illustrate potential for synergy between drug candidate GMI-1359 and PD-L1 antagonists when used in combination to treat solid tumors',2016-11-08 09:05:00-05:00,GLYC,positive
559536.0,GlycoMimetics Initiatl First Patient in Phase 1 Clinical Trial of Drug Candidate GMI-1271 for Multiple Myeloma,2016-09-14 09:15:00-04:00,GLYC,neutral
559537.0,GlycoMimetics Initiates Phase 1 Trial For GMI-1359,2016-09-06 09:16:00-04:00,GLYC,neutral
559538.0,GlycoMimetics Announces Publication of Preclinical Data Showing Drug Candidate GMI-1271 Reduces Inflammatory Responses After Heart Attack,2016-08-16 09:18:00-04:00,GLYC,negative
559539.0,GlycoMimetics Initiated At Outperform By Cowen And Company,2016-08-15 12:01:00-04:00,GLYC,neutral
559540.0,Benzinga's Top Initiations,2016-08-15 09:23:00-04:00,GLYC,positive
559541.0,Cowen & Company Initiates Coverage on GlycoMimetics at Outperform,2016-08-15 07:00:00-04:00,GLYC,neutral
559542.0,GlycoMimetics Reports Q2 EPS $(0.41) vs $(0.45) Est.,2016-08-04 17:47:00-04:00,GLYC,neutral
559543.0,Benzinga's Top Initiations,2016-07-26 09:35:00-04:00,GLYC,positive
559544.0,SunTrust Robinson Humphrey Initiates Coverage on GlycoMimetics at Buy,2016-07-26 07:40:00-04:00,GLYC,neutral
559545.0,GlycoMimetics Reports Dosing of First Patient in Phase 2 Trial of GMI-1271 in Newly Diagnosed AML,2016-06-28 09:06:00-04:00,GLYC,positive
559546.0,Mid-Afternoon Market Update: Crude Oil Up Over 3%; Lumber Liquidators Shares Spike Higher,2016-06-17 14:31:00-04:00,GLYC,negative
559547.0,5 Biggest Mid-Day Losers For Friday,2016-06-17 12:49:00-04:00,GLYC,negative
559548.0,Mid-Day Market Update: Dow Falls Over 100 Points; Elizabeth Arden Shares Jump Following Acquisition News,2016-06-17 12:11:00-04:00,GLYC,positive
559549.0,Mid-Morning Market Update: Markets Open Lower; Smith & Wesson Beats Q4 Expectations,2016-06-17 09:57:00-04:00,GLYC,negative
559550.0,GlycoMimetics Reports 3.3M Shares at $6.10/Share,2016-06-17 09:00:00-04:00,GLYC,positive
559551.0,GlycoMimetics Reports Proposed Public Offering of Common Stock,2016-06-16 16:01:00-04:00,GLYC,neutral
559552.0,GlycoMimetics Releases Poster from EHA Presentation,2016-06-10 06:40:00-04:00,GLYC,neutral
559553.0,GlycoMimetics Reports GMI-1271 Phase 1/2 Data: Showed Overall Response Rate 47% Among 19 Patients,2016-06-10 06:06:00-04:00,GLYC,neutral
559554.0,GlycoMimetics Reports Dosing of First Patient in Phase 2 Portion of GMI-1271 Trial in Relapsed/Refractory AML,2016-06-06 09:02:00-04:00,GLYC,positive
559555.0,GlycoMimetics Announces New Preclinical Data Of GMI-1271 In Science Transnational Medicine,2016-05-25 14:01:00-04:00,GLYC,neutral
559556.0,Initial Efficacy Data for GlycoMimetics' GMI-1271 Combined with Chemotherapy in Patients with AML to Be Presented at EHA 21st Congress,2016-05-19 09:31:00-04:00,GLYC,positive
559557.0,GlycoMimetics Reports Q1 EPS $(0.40) vs $(0.47) Est.,2016-05-04 09:00:00-04:00,GLYC,neutral
559558.0,GlycoMimetics Offers Data on GMI-1271 Treatment of Acetaminphen-Triggered Liver Toxicity at Conference,2016-04-25 16:32:00-04:00,GLYC,neutral
559559.0,GlycoMimetics Offers Initial Data from Phase 1 Trial of GMI-1271 in AML Patients: Overall Response Rate 62% in Initial 13 Patients,2016-03-02 08:31:00-05:00,GLYC,positive
559560.0,Filing from Glycomimetics Shows Co. Entered Sales Deal with Cowen for $19M in Common Stock,2016-03-01 16:05:00-05:00,GLYC,neutral
559561.0,"GlycoMimetics Reports Q4 EPS $(0.47) vs $(0.43) Est., Sales $35K vs $700K Est.",2016-02-29 17:03:00-05:00,GLYC,neutral
559562.0,GlycoMimetics Announces Preclinical Data Shows GMI-1271 Reverses Drug Resistance in Multiple Myeloma Models at #ASH15,2015-12-05 10:16:00-05:00,GLYC,neutral
559563.0,GlycoMimetics Reports Q3 EPS $(0.38) Vs Est $(0.40),2015-11-12 09:30:00-05:00,GLYC,neutral
559564.0,GlycoMimetics Reports Issuance of U.S. Composition of Matter Patent for Drug Candidate GMI-1271,2015-08-31 16:30:00-04:00,GLYC,neutral
559565.0,"GlycoMimetics Reports Q2 EPS $0.51 vs. Est. $(0.40) Does Not Compare, Rev. $20.035M",2015-08-06 16:49:00-04:00,GLYC,neutral
559566.0,"GlycoMimetics Reports Q2 EPS $0.51 May Not Compare, Sales $20M No Estimates",2015-08-06 16:35:00-04:00,GLYC,negative
559567.0,GlycoMimetics Receives $20M Payment From Pfizer Following Phase 3 Initiaion Of Rivipansel,2015-06-23 14:21:00-04:00,GLYC,neutral
559568.0,GlycoMimetics Initiates Phase 1/2 Clinical Trial of GMI-1271 as Potential Treatment for Acute Myeloid Leukemia in Combination with Chemotherapy,2015-05-19 09:31:00-04:00,GLYC,neutral
559569.0,FDA Grants Orphan Drug Designation To GlycoMimetics' GMI-1271 For Treatment of Acute Myleogenous Leukemia,2015-05-14 10:32:00-04:00,GLYC,positive
559570.0,GlycoMimetics Offers Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-'15: Co. to Receive $20M Milestone Payment Upon First Patient Dosing,2015-04-07 07:01:00-04:00,GLYC,neutral
559571.0,Glycomimetics Files for Up to $150M Mixed Shelf,2015-03-17 06:07:00-04:00,GLYC,neutral
559572.0,"GlycoMimetics Reports Q4 EPS $(0.39) vs. Est. $(0.22), Rev. $0M vs. Est. $3.33M",2015-03-16 16:32:00-04:00,GLYC,neutral
559573.0,GlycoMimetics Announces Publication of Phase 2 Data for Rivipansel in Sickle Cell Disease,2015-03-03 09:02:00-05:00,GLYC,neutral
559574.0,GlycoMimetics Announces Positive Top-Line Results from Phase 1 Study of GMI-1271,2014-11-17 16:00:00-05:00,GLYC,positive
559575.0,Morning Market Losers ,2014-09-26 09:45:00-04:00,GLYC,negative
559576.0,GlycoMimetics Reports Delay in Initiation of Phase 3 Trial with Rivipansel,2014-09-26 09:03:00-04:00,GLYC,negative
559577.0,Upcoming Corporate Events/Presentations for the Week of Aug. 11-15th,2014-08-11 11:54:00-04:00,GLYC,neutral
559578.0,"GlycoMimetics Q2 Revenue $15M, EPS 0.39",2014-07-31 16:22:00-04:00,GLYC,neutral
559579.0,GlycoMimetics Reports Deal with FDA on SPA for Phase 3 Clinical Trial for Rivipansel Trial,2014-07-01 09:03:00-04:00,GLYC,neutral
559580.0,GlycoMimetics Gets $15M Payment From Pfizer For Development of Rivipansel,2014-05-20 16:01:00-04:00,GLYC,neutral
559581.0, GlycoMimetics Expects Advance Milestone Payment of $15M from Pfizer in Q2,2014-05-08 09:04:00-04:00,GLYC,neutral
559582.0,"Stifel Nicolaus Maintains Buy on GlycoMimetics, Raises PT to $16.00",2014-04-15 06:59:00-04:00,GLYC,neutral
559583.0,UPDATE: Barclays Initiates Coverage on GlycoMimetics,2014-02-04 10:50:00-05:00,GLYC,neutral
559584.0,"Stifel Nicolaus Initiates Coverage on GlycoMimetics at Buy, Announces $14.00 PT",2014-02-04 07:10:00-05:00,GLYC,neutral
559585.0,"Barclays Initiates Coverage on GlycoMimetics at Overweight, Announces $15.00 PT",2014-02-04 07:04:00-05:00,GLYC,negative
559586.0,Investors Finding Safety in Today's IPOs,2014-01-24 12:28:00-05:00,GLYC,positive
559587.0,GlycoMimetics Revises IPO to 5.75M Shares at $8.00/Share,2014-01-07 06:17:00-05:00,GLYC,positive
559588.0,GlycoMimetics Files Registration Statement for Proposed IPO,2013-10-07 06:42:00-04:00,GLYC,neutral
